Fibrinogen in Liver Transplant
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Intercept Fibrinogen Complex (IFC), Cryoprecipitate Antihemophilic Factor (AHF).
- Who it may be relevant to
- Registry conditions: Liver Transplant Surgery. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Fibrinogen in Liver Transplant Subjects (FITS)
Overview
The study is a prospective, multi-centered, unblinded, randomized controlled pilot study. The primary objective is to compare functional hemostatic capacity of two approved products Intercept Fibrinogen Complex (IFC) to Standard Cryoprecipitate Antihemophilic Factor (AHF) for liver transplant patients with bleeding and hypofibrinogenemia to determine impact of earlier access to a concentrated source of fibrinogen in a goal-directed manner.
Detailed description
Fibrinogen is an important factor for hemostasis and when it is deficient or dysfunctional replacing it will improve hemostasis and reduce bleeding. Observational data indicates the use of cryoprecipitate as a source of fibrinogen may reduce bleeding and improve outcomes in patients with severe bleeding. Liver transplant patients often become hypofibrinogenemic and may benefit from early goal directed use of cryoprecipitate or IFC. IFC can be more readily available since it can be stored at room temperature compared to cryoprecipitate which requires thawing. As a result, IFC can be immediately available when indicated compared to the delay in administration of cryoprecipitate due to the need for it to be thawed. This trial will compare clinical outcomes for subjects randomized to either cryoprecipitate or IFC in bleeding liver transplant patients with reduced fibrinogen function.
There is no data comparing outcomes for subjects receiving IFC or cryoprecipitate in any patient population.
The rationale for this trial is to compare IFC to cryoprecipitate (cryo) to assist with the design of a future definitive multicenter trial. Potential advantages of IFC are that since it is stored at room temperature it can be made immediately available whereas with cryo the delay in treatment can be 30 to 40 min due to the need to thaw it from a frozen state. The reduced time to treatment of bleeding may improve outcomes with the use of IFC compared to cryo. In vitro data indicates similar hemostatic function between IFC and Cryo. IFC is pathogen reduced cryoprecipitate. The pathogen reduction methods are licensed for IFC and there has been no safety concerns regarding its use at the centers that are currently using it as their standard product (unpublished).
Interventions
- Biological Intercept Fibrinogen Complex (IFC)
INTERCEPT Fibrinogen Complex is a pathogen-reduced cryoprecipitated fibrinogen complex derived from human plasma. It contains fibrinogen, Factor XIII, and von Willebrand factor to achieve stable clot formation and restore hemostasis. Recently approved by the US Food and Drug Administration, it is used for the treatment of bleeding associated with fibrinogen deficiency. - Biological Cryoprecipitate Antihemophilic Factor (AHF)
Cryoprecipitate Antihemophilic Factor (AHF), also known as cryo, is a frozen blood product prepared from blood plasma. It is used for fibrinogen supplementation, particularly for hypofibrinogenemia fibrinogen, anemia associated with bleeding or congenital deficiency.
Primary outcome measures
- Amount of blood products (24-hours) [Time Frame: 24-hours after initial blood product administration] [Time frame: 24-hour]
Secondary outcome measures (3)
- Change in Visoelastic parameters [Time Frame: pre-intervention through 24 hours post intervention] [Time frame: pre intervention through 24 hours post intervention]
- Costs of blood products [Time Frame: 24 hours] [Time frame: 24 hours post-surgery]
- Costs of IV hemostatic agents [Time Frame: 24 hours] [Time frame: 24 hours post-surgery]
Eligibility criteria
Inclusion criteria
- 18 years of age or older
- Scheduled to undergo cadaveric liver transplant
- Meets at least one of the following criteria:
- Baseline fibrinogen <200 mg/dL or clinically significant visoelastic testing,
- Alcoholic cirrhosis,
- Nonalcoholic Steatohepatitis (NASH),
- HCV infection
Exclusion criteria
- Living related donor transplant,
- Known prothrombotic disorder,
- Patient objection to blood transfusion,
- Known severe allergic reaction to plasma-based products,
- IgA deficiency with known hypersensitivity reaction to plasma,
- Hepatocellular/cholangio carcinoma,
- Primary biliary fibrosis
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
United States · 1 center
- University of Cincinnati — Cincinnati
Identifiers
NCT: NCT07265843 · FITS